RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER

Depression and Anxiety

Volumn 33, Issue 8, 2016, Pages 737-745

  Otto, Michael W ^a   Pollack, Mark H ^b   Dowd, Sheila M ^b   Hofmann, Stefan G ^a   Pearlson, Godfrey ^c   Szuhany, Kristin L ^a   Gueorguieva, Ralitza ^d   Krystal, John H ^c   Simon, Naomi M ^e   Tolin, David F ^c  

^a BOSTON UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

anxiety; CBT; clinical trials; panic attacks agoraphobia; pharmacotherapy

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CYCLOSERINE; PLACEBO;

ADULT; AGITATION; ANXIETY; ANXIETY ASSESSMENT; ARTICLE; BLURRED VISION; CHILL; COGNITIVE BEHAVIORAL THERAPY; CONCENTRATION LOSS; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; NAUSEA AND VOMITING; NERVOUSNESS; PANIC; PANIC DISORDER SEVERITY SCALE; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESSNESS; SELF HELP; SIDE EFFECT; TACHYCARDIA; TREMOR; XEROSTOMIA;

EID: 84979656535     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22531     Document Type: Article

References (39)

1. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000;283(19):2529–2536.
2. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005;88(1):27–45.
3. Hofmann SG, Barlow DH, Papp LA, et al. Pretreatment attrition in a comparative treatment outcome study on panic disorder. Am J Psychiatry 1998;155(1):43–47.
4. Tsao JC, Lewin MR, Craske MG. The effects of cognitive-behavior therapy for panic disorder on comorbid conditions. J Anxiety Disord 1998;12(4):357–371.
5. McHugh RK, Otto MW, Barlow DH, et al. Cost-efficacy of individual and combined treatments for panic disorder. J Clin Psychiatry 2007;68(7):1038–1044.
6. Otto MW, Pollack MH, Maki KM. Empirically supported treatments for panic disorder: costs, benefits, and stepped care. J Consult Clin Psychol 2000;68(4):556–563.
7. Pollack MH, Otto MW, Roy-Byrne PP, et al. Novel treatment approaches for refractory anxiety disorders. Depress Anxiety 2008;25(6):467–476.
8. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry 2006;188:305–312.
9. Watanabe N, Churchill R, Furukawa TA. Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review. BMC Psychiatry 2007;7:18–30.
10. Burghardt NS, Sigurdsson T, Gorman JM, et al. Chronic antidepressant treatment impairs the acquisition of fear extinction. Biol Psychiatry 2013;73(11):1078–1086.
11. Otto MW, McHugh RK, Kantak KM. Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: medication effects, glucocorticoids, and attenuated treatment outcomes. Clin Psychol 2010;17(2):91–103.
12. Rothbaum BO, Price M, Jovanovic T, et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry 2014;171(6):640–648.
13. Anderson KC, Insel TR. The promise of extinction research for the prevention and treatment of anxiety disorders. Biol Psychiatry 2006;60(4):319–321.
14. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004;61(11):1136–1144.
15. Otto MW, Kredlow MA, Smits JA, et al. Enhancement of psychosocial treatment with d-cycloserine: models, moderators, and future directions. Biol Psychiatry in press.
16. Rodrigues H, Figueira I, Lopes A, et al. Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PLoS One 2014;9(7):e93519.
17. Otto MW, Tolin DF, Simon NM, et al. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 2010;67(4):365–370.
18. Siegmund A, Golfels F, Finck C, et al. D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res 2011;45(8):1042–1047.
19. Chasson GS, Buhlmann U, Tolin DF, et al. Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther 2010;48(7):675–679.
20. Hofmann SG, Smits JA, Rosenfield D, et al. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry 2013;170(7):751–758.
21. Andersson E, Hedman E, Enander J, et al. D-cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: a randomized clinical trial. JAMA Psychiatry 2015;72(7):659–667.
22. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID I/P, Version 2.0). New York: Biometrics Research Department; 1995.
23. Di Nardo PAB TA, Barlow DH. Anxiety Disorders Interview Schedule for DSM-IV: Lifetime Version (ADIS-IV-L). New York: Oxford University Press; 1994.
24. Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry 1997;154(11):1571–1575.
25. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare; 1976.
26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.
27. Shear MK, Vander Bilt J, Rucci P, et al. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety 2001;13(4):166–178.
28. Leon AC, Solomon DA, Mueller TI, et al. A brief assessment of psychosocial functioning of subjects with bipolar I disorder: the LIFE-RIFT. Longitudinal interval follow-up evaluation-range impaired functioning tool. J Nerv Ment Dis 2000;188(12):805–812.
29. Peterson RA, Reiss S. Anxiety Sensitivity Index Manual. Worthington, OH: International Diagnostic Services, Inc.; 1992.
30. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993;29(2):321–326.
31. Otto MW, Tolin DF, Nations KR, et al. Five sessions and counting: considering ultra-brief treatment for panic disorder. Depress Anxiety 2012;29(6):465–470.
32. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004;61(3):310–317.
33. Paul IA, Nowak G, Layer RT, et al. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994;269(1):95–102.
34. Westra HA, Stewart SH, Conrad BE. Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia. J Anxiety Disord 2002;16(3):233–246.
35. Otto MW, McHugh RK, Simon NM, et al. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: further evaluation. Behav Res Ther 2010;48(8):720–727.
36. Farrell LJ, Waters AM, Boschen MJ, et al. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy. Depress Anxiety 2013;30(8):723–731.
37. Norberg MM, Gilliam CM, Villavicencio A, et al. D-cycloserine for treatment nonresponders with obsessive-compulsive disorder: a case report. Cogn Behav Pract 2012;19:338–345.
38. Smits JA, Rosenfield D, Otto MW, et al. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res 2013;47(10):1455–1461.
39. Smits JA, Rosenfield D, Otto MW, et al. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 2013;73(11):1054–1058.